Quercetin and rutin as potential agents antifungal against Cryptococcus spp

Oliveira, V. M.; Carraro, E.; Auler, M. E.; Khalil, N. M.
October 2016
Brazilian Journal of Biology;Oct-Dec2016, Vol. 76 Issue 4, p1029
Academic Journal
Amphotericin B is a fungicidal substance that is treatment of choice for most systemic fungal infections affecting as cryptococcosis the immunocompromised patients. However, severe side effects have limited the utility of this drug. The aim of this study was to evaluate the antifungal effect of the combination of amphotericin B with quercetin or rutin and as a protective of citotoxic effect. The antifungal activity to amphotericin B, quercetin and rutin alone and in combination was determined in Candida sp and Cryptococcus neoformans strains. Cytotoxicity test on erythrocytes was performed by spectrophotometric absorbance of hemoglobin. The amphotericin B MIC was reduced when used in combination with quercetin or rutin to C. neoformans ATCC strain and reduced when combined with rutin to a clinical isolate of C. neoformans. In addition, the combination of quercetin with amphotericin B may reduce the toxicity of amphotericin B to red blood cells. Our results suggest that quercetin and rutin are potential agents to combine with amphotericin B in order to reduce the amphotericin dose to lessen side effects and improve antifungal efficacy.


Related Articles

  • Effects of Pimenta pseudocaryophyllus (Gomes) L. R. Landrum, on Melanized and Non-melanized Cryptococcus neoformans. Fátima Lisboa Fernandes, Orionalda; Costa, Carolina; Souza Lino Junior, Ruy; Vinaud, Marina; Hasimoto e Souza, Lúcia; Paula, Joelma; Rosário Rodrigues Silva, Maria // Mycopathologia;Dec2012, Vol. 174 Issue 5/6, p421 

    In the present study, the in vitro susceptibility and capsular width from both melanized and non-melanized Cryptococcus neoformans cells in the presence of Pimenta pseudocaryophyllus crude extract were determined. The results were compared with those obtained for voriconazole and amphotericin B....

  • Antifungal Susceptibilities of Cryptococcus neoformans. Archibald, Lennox K.; Tuohy, Marion J.; Wilson, Deborah A.; Nwanyanwu, Okey; Kazembe, Peter N.; Tansuphasawadikul, Somsit; Eampokalap, Boonchuay; Chaovavanich, Achara; Reller, L. Barth; Jarvis, William R.; Hall, Gerri S.; Procop, Gary W. // Emerging Infectious Diseases;Jan2004, Vol. 10 Issue 1, p143 

    Susceptibility profiles of medically important fungi in less-developed countries remain uncharacterized. We measured the Mits of amphotericin B, 5-flucytosine, fluconazole, itraconazole, and ketoconazole for Cryptococcus neoformans clinical isolates from Thailand, Malawi, and the United States...

  • Disseminated cryptococcosis in a patient with nephrotic syndrome. Qadir, F.; Manzoor, K.; Ahmed, E. // Indian Journal of Medical Microbiology;Apr2006, Vol. 24 Issue 2, p141 

    Disseminated cryptococcosis mainly occurs in patients with impaired cell mediated immunity. We present a case of disseminated cryptococcosis in a non-HIV patient with nephrotic syndrome who never received immunosuppression. Cultures of bone marrow aspirate, cerebrospinal fluid analysis and...

  • Pleural effusion as the initial clinical presentation in disseminated cryptococcosis and fungaemia: an unusual manifestation and a literature review. Mayun Chen; Xiaomi Wang; Xianjuan Yu; Caijun Dai; Dunshun Chen; Chang Yu; Xiaomei Xu; Dan Yao; Li Yang; Yuping Li; Liangxing Wang; Xiaoying Huang; Chen, Mayun; Wang, Xiaomi; Yu, Xianjuan; Dai, Caijun; Chen, Dunshun; Yu, Chang; Xu, Xiaomei; Yao, Dan // BMC Infectious Diseases;9/23/2015, Vol. 15 Issue 1, p1 

    Background: Cryptococcus neoformans infection usually presents as chronic meningitis and is increasingly being recognized in immunocompromised patients. Presentation with pleural effusion is rare in cryptococcal disease; in fact, only 4 cases of pleural effusion as the initial...

  • Cryptococcosis in China (1985-2010): Review of Cases from Chinese Database. Yuchong, Chen; Fubin, Che; Jianghan, Chen; Fenglian, Wei; Nan, Xu; Minghui, Yang; Yalin, Sun; Zhizhong, Zheng // Mycopathologia;Jun2012, Vol. 173 Issue 5/6, p329 

    Background: Cryptococcosis is a potential fatal disease, especially in immunocompromised patients. In China, the profile of cryptococcosis is unclear. Therefore, we summarize the epidemiology and therapy of cryptococcosis in china. Methods: All cases reports about cryptococcosis in China were...

  • Pulmonary cryptococcosis in non-AIDS patients. Benquan Wu; Hui Liu; Jing Huang; Wenxian Zhang; Tiantuo Zhang // Clinical & Investigative Medicine;Feb2009, Vol. 32 Issue 1, pE70 

    Purpose: To clarify the clinical features and imaging characteristics of non-AIDS patients with pulmonary cryptococcosis. Methods: We retrospectively collected 15 HIV-negative patients with pathology-proved pulmonary cryptococcosis from Sep1992 to Jan 2008. Their medical records and radiological...

  • Resistance of Asian Cryptococcus neoformans Serotype A Is Confined to Few Microsatellite Genotypes. Weihua Pan; Kantarawee Khayhan; Ferry Hagen; Retno Wahyuningsih; Chakrabarti, Arunaloke; Chowdhary, Anuradha; Ikeda, Reiko; Taj-Aldeen, Saad J.; Khan, Ziauddin; Imran, Darma; Sjam, Ridhawati; Sriburee, Pojana; Wanqing Liao; Chaicumpar, Kunyaluk; Ingviya, Natnicha; Mouton, Johan W.; Curfs-Breuker, Ilse; Boekhout, Teun; Meis, Jacques F.; Klaassen, Corné H. W. // PLoS ONE;Mar2012, Vol. 7 Issue 3, p1 

    Background: Cryptococcus neoformans is a pathogenic yeast that causes cryptococcosis, a life threatening disease. The prevalence of cryptococcosis in Asia has been rising after the onset of the AIDS epidemic and estimates indicate more than 120 cases per 1,000 HIV-infected individuals per year....

  • Lipid Formulations of Amphotericins: Are You a Lumper or a Splitter? Wingard, John R. // Clinical Infectious Diseases;10/1/2002, Vol. 35 Issue 7, p891 

    Editorial. Analyzes the wisdom of grouping together lipid formulations of amphotericin as alternatives to conventional amphotericin B for empirical antifungal therapy. Pharmacokinetic differences in the formulations; Difference in mortality rates; Differences in efficacy.

  • Continuous Infusion of Escalated Doses of Amphotericin B Deoxycholate: An Open-Label Observational Study. Imhof, Alexander; Walter, Roland B.; Schaffner, Andreas // Clinical Infectious Diseases;4/15/2003, Vol. 36 Issue 8, p943 

    Reports on amphotericin B deoxycholate (AmB-d) that remains a mainstay of antifungal therapy for immunocompromised patients, despite being associated with therapy-related toxicity. Median duration of AmB-d therapy; Possibility of dose escalation without delay in 28 patients.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics